Complement inhibition attenuates brain edema and neurological deficits induced by thrombin* by Y Gong1 et al.
Acta Neurochir (2005) [Suppl] 95: 389–392
6 Springer-Verlag 2005
Printed in Austria
Complement inhibition attenuates brain edema and neurological deficits induced
by thrombin*
Y. Gong1, G. H. Xi1, R. F. Keep1,2, J. T. Ho¤1, and Y. Hua1
1Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
2Department of Physiology, University of Michigan, Ann Arbor, Michigan, USA
Summary
The present study examined whether thrombin activates the
complement cascade in the brain and whether N-acetylheparin, an
inhibitor of complement activation, attenuates brain injury induced
by thrombin. There were three sets of studies. In the first set, rats
had an intracerebral infusion of either five-unit thrombin or a
needle insertion. Brains were sampled at 24 hours for Western blot
analysis and immuno-histochemistry. In the second set, rats received
either five-unit thrombinþsaline, five-unit thrombinþ25 mg N-
acetylheparin or five-unit thrombinþ100 mg N-acetylheparin infu-
sion. Brains were sampled 24 hours later for water content measure-
ment. In the third set, rats received either five-unit thrombinþsaline
or five-unit thrombinþ100 mg N-acetylheparin. Behavioral tests sen-
sitive to unilateral striatal damage were carried out for two weeks.
Western blotting demonstrated that complement C9 and clusterin
levels increase 24 hours after thrombin infusion (P < 0:01). Both
C9 and clusterin positive cells were found around the injection site.
High-dose (100-mg) but not low-dose (25-mg) N-acetylheparin atten-
uated thrombin-induced brain edema (81.5G 0.4% vs. 83.7G 0.3%
in the vehicle, P < 0:05). Behavior was also significantly improved
by N-acetylheparin (P < 0:05). In conclusion, thrombin-induced
edema formation and neurological deficits were both reduced by N-
acetylheparin. This suggests that inhibition may be a novel treatment
for the thrombin-induced brain injury that occurs in intracerebral
hemorrhage.
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Introduction
Mechanisms of edema formation after intracerebral
hemorrhage (ICH) have been identified during the past
decade [14]. We now know that several processes
are responsible for edema formation around the clot.
These include hydrostatic pressure during the clot for-
mation, clot retraction, coagulation cascade activation
with thrombin production, erythrocyte lysis with he-
moglobin induced toxicity, and complement cascade
activation in the brain parenchyma [14].
Thrombin, in particular, has been shown to play a
major role in early edema formation after ICH. In-
deed, a thrombin inhibitor (argatroban) reduced ICH-
induced edema formation when given after six hours in
a rat ICH model [9] and there is some evidence to sup-
port human e‰cacy [11].
The present study, therefore, examined whether
thrombin can activate the complement cascade and




The protocols for these animal studies were approved by the Uni-
versity of Michigan Committee on the Use and Care of Animals.
Adult male Sprague-Dawley rats (275–325 g, Charles River Labora-
tories, Portage, Michigan) were anesthetized with pentobarbital
(40 mg/kg, i.p.). Aseptic precautions were utilized in all procedures.
A polyethylene catheter (PE-50) was then inserted into the right fem-
oral artery in order to monitor arterial blood pressure and to obtain
blood samples for analysis of blood gases, blood pH, hematocrit,
blood glucose concentration. Body temperature was maintained at
37.5 C by using a feedback-controlled heating pad.
Intracerebral infusion
Before intracerebral infusion, the rats were positioned in a stereo-
tactic frame (Kopf Instrument, Tujunga, CA), the scalp was incised
along the sagittal midline using a sterile technique. A cranial burr
hole (1 mm) was drilled near the right coronal suture 4.0 mm lateral
to the midline and a 26-gauge needle was inserted stereotaxically into
the right basal ganglia (coordinates: 0.2 mm anterior, 5.5 mm ven-
tral, and 4.0 mm lateral to the bregma). Thrombin, saline or throm-
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bin plus N-acetylheparin were infused at 5 ml/min into the right basal
ganglia using a microinfusion pump. After infusion, the needle was
removed and the skin incisions were closed with sutures. Animals
were allowed to recover.
Experiment groups
There were three sets of studies. In the first set, rats had intracere-
bral infusion of either five-unit thrombin or a needle insertion. Brains
were sampled at 24 hours for Western blot analysis and immuno-
histochemistry. In the second set, rats received either five-unit
thrombinþsaline, five-unit thrombinþ25 mg N-acetylheparin or
five-unit thrombinþ100 mg N-acetylheparin infusion. Brains were
sampled 24 hours later for water content measurement. In the third
set, rats received either five-unit thrombinþsaline or five-unit
thrombinþ100 mg N-acetylheparin. Behavioral tests sensitive to uni-
lateral striatal damage were carried out for two weeks.
Brain water content measurement
The rats were sacrificed by decapitation under deep pentobarbital
anesthesia (60 mg/kg i.p.). The brains were removed immediately
and a 3 mm thick coronal brain slice 4 mm from the frontal pole
was cut. That slice was divided into four samples, ipsilateral and con-
tralateral basal ganglia, and ipsilateral and contralateral cortex. Cer-
ebellum was obtained as a control. Tissue samples were weighed on
an electronic analytical balance to obtain the wet weight (WW). The
tissue was then dried in a gravity oven at 100 C for more than 24
hours to determine the dry weight (DW). Tissue water contents (%)
were calculated as [(WWDW)/WW] 100.
Western blot analysis
The rat brains were perfused with saline, and a coronal brain slice
was cut as described for brain water content measurements. The
brain tissue was immersed in 0.5 ml of Western blot sample bu¤er
and then sonicated forWestern blot analysis [15]. Primary antibodies
were rabbit anti-complement C9 polyclonal antibody (gift from Dr.
P. Morgan, University of Wales) and rabbit anti-clusterin polyclonal
antibody (gift fromDr. M. Griswold, Washington State University).
The relative densities of complement C9 and clusterin protein bands
were analyzed using the NIH image software.
Immuno-histochemistry
Immuno-histochemical studies were performed according to our
previous report [15]. Brain sections were incubated according to the
avidin-biotin complex technique. Primary antibodies were rabbit
anti-complement C9 polyclonal antibody (gift from Dr. P. Morgan,
University of Wales) and rabbit anti-clusterin polyclonal antibody
(gift from Dr. M. Griswold, Washington State University). Normal
rabbit IgG was used as negative control.
Behavioral tests
Animals were placed in a cylindrical enclosure to record preferen-
tial use of the non-impaired forelimb for weight shifting movements
during spontaneous vertical exploration. The percentage indepen-
dent use of the non-impaired forelimb (ipsilateral to the injection
side), that for the contralateral forelimb, or for both forelimbs to-
gether in rapid succession for stepping movements along the walls
of the cylinder were calculated. A single score was then used to reflect
forelimb use asymmetry: percentage ipsilateral limb use minus per-
centage contralateral limb use (low score ¼ better function). In addi-
tion, a vibrissae-stimulated forelimb placing test (10 trials per side
for each rat) was used to examine sensorimotor/proprioceptive ca-
pacity (high score ¼ better function) [6]. All behavior was scored
by experimenters who were blind to both neurological and treatment
conditions. These tests are highly correlated with extent of striatal in-
jury without being influenced by repeated testing.
Statistical analysis
All data in this study are presented as meanG standard deviation.
Data were analyzed with ANOVA using the Sche¤e F test or Mann-
Whitney U rank test. Significance levels were measured at P < 0:05.
Results
Mean arterial pressure, blood pH, arterial oxygen
and carbon dioxide tensions, hematocrit, and blood
glucose were controlled within normal ranges.
Western blot analysis demonstrated that C9 had a
seven-fold increase 24 hours after intracerebral infu-
sion of five-unit thrombin (3329G 433 vs 458G 395
pixels in saline control, P < 0:01). Immuno-histo-
chemistry showed that C9 was deposited on neuronal
membranes, indicating activation of the complement
cascade and the formation of membrane attack com-
plex. Clusterin, an inhibitor of membrane attack com-
plex formation, also increased after thrombin infusion
(4925G 686 vs 2453G 264 pixels in saline control,
P < 0:01) and was expressed in neurons.
High-dose (100 mg) but not low-dose (25 mg) N-
acetylheparin attenuated thrombin-induced brain
edema (81.5G 0.4% vs 83.7G 0.3% in the vehicle,
P < 0:05; Fig. 1). Forelimb use asymmetry score and
forelimb placing score were also significantly im-
proved by high-dose N-acetylheparin (P < 0:05; Fig.
2).
Discussion
In the present study, we demonstrated that
thrombin can increase complement C9 and clusterin
levels in the brain. Complement inhibition with N-
acetylheparin, a heparin congener without anticoa-
gulant properties, reduced thrombin-induced brain
edema and neurological deficits.
The complement system is involved in various im-
mune reactions, including cell lysis and the inflamma-
tory response [12]. Complement is normally excluded
from the brain parenchyma by the blood-brain barrier
(BBB), but entry can occur after ICH as a part of the
extravasated blood and later as a result of BBB disrup-
tion. There is evidence that the complement cascade is
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activated in brain parenchyma after ICH. Our previ-
ous studies have found that inhibition and depletion
of the complement cascade attenuate perihematomal
brain edema [7, 13].
The current study indicates that thrombin can acti-
vate the complement cascade in the brain. Intracere-
bral infusion of thrombin resulted in a seven-fold
increase in complement C9 and a deposition of com-
plement C9 on neuronal membranes. Complement-
related brain injury may be due to membrane attack
complex (MAC) formation and the classic inflamma-
tory response. MAC consists of C5b-9 complement
forms which are assembled following complement
activation [3]. The presence of C9 on cell membranes
is an indicator of MAC formation. Its formation
causes the production of a pore in the cell membrane
that leads to cell lysis. Thus, MAC formation may be
involved in the lysis of erythrocytes within the clot
after ICH. However, MAC insertion may also occur
in neurons, glia and endothelial cells, causing neu-
ronal death and BBB leakage. Our studies have also
shown that MAC is assembled after ICH [7]. Recent
studies have demonstrated that MAC not only causes
cell lysis, but also modulates cellular functions such as
the release of cytokines, oxygen radicals, and matrix
proteins [5].
Clusterin, an inhibitor of MAC formation, was also
up-regulated and found in neurons after intracerebral
thrombin infusion. We have also found that it is up-
regulated in the brain parenchyma after ICH [7]. The
balance between complement activation and clusterin
up-regulation may help to determine the extent of
brain injury.
The e¤ects of coagulation cascade on comple-
ment activation are not well studied. However, several
studies suggest that there is a very close relationship
between thrombin and complement. About 50% of
C3 is cleaved during clot formation [4]. Thrombin can
cleave and activate C3 [1]. Thrombin cleaved C3a like
fragments are chemotatic for leukocytes and to induce
enzyme release from neutrophils [8]. Thrombin can
also cleave C5 to produce C5a like fragments which
are leukotactic [8].
Although the primary role of thrombin in hemosta-
sis is through cleaving fibrinogen to fibrin and inducing
platelet aggregation, other important cellular activities
of thrombin may be related to thrombin receptor
activation [16]. Three protease-activated receptors
(PARs), PAR-1, PAR-3 and PAR-4, have been identi-
fied as thrombin receptors [2]. Little is known about
Fig. 1. Brain water content 24 hours after intracerebral infusion of
5 units thrombin, thrombin 5 unitsþ 25 mg N-acetyheparin, and
thrombin 5 unitsþ 100 mg N-acetyheparin. Values are meanGSD,
n ¼ 5, *P < 0:05 vs. thrombin
Fig. 2. Forelimb use asymmetry (low score ¼ better function; a) and
forelimb placing score (high score ¼ better function; b) at days 1, 3,
5, 7 and 14 after incerebral infusion of 5 units thrombin or 5 units
thrombinþ 100 mg N-acetyheparin. Values are meanG SD, n ¼ 8,
#P < 0.01 and *P < 0:05, Mann-Whitney U rank test
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the interaction between the activation of PARs and the
complement system. Lidington et al. [10] found that
thrombin stimulates decay-accelerating factor (DAF)
production through PAR-1. However, whether the ef-
fects of thrombin on the complement system found in
this study are PAR mediated is still uncertain.
In conclusion, thrombin-induced edema formation
and neurological deficits were both reduced by N-
acetylheparin suggesting that complement inhibition
may be a novel treatment for ICH.
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